0000882291
false
0000882291
2023-11-14
2023-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 14, 2023
AETHLON
MEDICAL, INC.
(Exact name of Registrant as Specified in Its
Charter)
Nevada |
001-37487 |
13-3632859 |
(State or Other Jurisdiction of
Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
11555
Sorrento Valley Road, Suite
203
San Diego, California |
92121 |
(Address of Principal Executive Offices) |
(Zip Code) |
Registrant’s Telephone Number, Including
Area Code: (619) 941-0360
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
AEMD |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.02 |
Results of Operations and Financial Condition. |
On November 14, 2023, Aethlon Medical, Inc. issued
a press release announcing its financial results for the quarter ended September 30, 2023. A copy of this press release is attached hereto
as Exhibit 99.1.
The information in this Item 2.02 and the exhibit
hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 14, 2023 |
Aethlon Medical, Inc. |
|
|
|
|
|
|
|
By: |
/s/ James B. Frakes |
|
Name:
|
James B. Frakes
Interim Chief Executive Officer and Chief Financial Officer |
Exhibit 99.1
Aethlon Medical
Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
Conference Call to be Held Today at 4:30
p.m. ET
SAN DIEGO, November 14, 2023 -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases,
today reported financial results for its fiscal second quarter ended September 30, 2023 and provided an update on recent developments.
Company Updates
Aethlon Medical is continuing the research and
clinical development of its Hemopurifier®, a therapeutic blood filtration system that can bind to and remove harmful exosomes
and life-threatening viruses from blood. These qualities of the Hemopurifier have potential applications in oncology, where cancer associated
exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. Aethlon also recently announced that
it is investigating the use of the Hemopurifier in the organ transplant setting, initially focusing on the potential removal of harmful
viruses and exosomes from recovered kidneys.
In October, Aethlon received clearance from the
Drug Controller General of India (DCGI), the central drug authority in India, to conduct a phase 1 safety, feasibility and dose-finding
trial of the company's Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy
treatment, such as Keytruda® or Opdivo®. The trial is expected to begin following completion of an internal in vitro binding study
of relevant targets, and subsequent approval by the respective Ethics Boards of interested sites in India.
Aethlon announced yesterday that, effective as
of November 7, 2023, James B. Frakes, M.B.A., Chief Financial Officer of the company, was appointed as Interim Chief Executive Officer,
replacing Charles J. Fisher, Jr. M.D., and also was appointed as a member of the company’s Board of Directors. Mr. Frakes also will
remain as Chief Financial Officer of the company. Also effective as of November 7, 2023, Guy F. Cipriani, formerly Chief Business Officer
of the company, was appointed as the Company's Chief Operating Officer and resigned from the company's Board of Directors
“On behalf of everyone at Aethlon Medical,
we would like to thank Dr. Fisher for his service to the company as our CEO and as a member of our Board of Directors,” stated Mr.
Frakes.“ I am grateful for our Board’s confidence in me. I am deeply committed to Aethlon’s shareholders and employees,
and plan to work tirelessly to help the company succeed. I look forward to continuing the development of the Hemopurifier, and initiating
a potential Phase 1 trial in oncology in both India and Australia, an area where we see great promise and ongoing emphasis.”
We previously reported a disruption in our Hemopurifier
supply and that our intended transition to a new supplier for galanthus nivalis agglutinin, or GNA, a component of our Hemopurifier,
was delayed as we work with the FDA for approval of our supplement to our IDE, which is required to make this manufacturing change. We
are continuing to work with the FDA to qualify this second supplier of our GNA, but are in the process of completing final testing to
begin manufacturing Hemopurifiers at our new manufacturing facility in San Diego for use in U.S. clinical trials, using GNA from our original
GNA supplier. The company has a sufficient supply of Hemopurifiers for use in our planned oncology trial in Australia and India.
Financial Results for the Second Quarter Ended
June 30, 2023
As of September 30, 2023, Aethlon Medical had
a cash balance of approximately $10.2 million.
Consolidated operating expenses for the three
months ended September 30, 2023 were approximately $3.2 million, compared to $3.7 million for the three months ended September 30, 2022.
This decrease of approximately $500,000, or 13.4%, in the 2023 period was due to decreases in general and administrative expenses of approximately
$700,000, offset by increases in professional fees of approximately $129,000, and an increase in our payroll and related expenses of $78,000.
The $700,000 decrease in general and administrative
expenses was primarily due to the combination of a $377,000 decrease in clinical trial expenses associated with the closed COVID trial,
a $261,000 decrease in the purchase of raw materials for research and development testing for use in the Hemopurifier, a $140,000 decrease
in subcontract expenses associated with previous government contracts and a $64,000 decrease in rent related to previously rented mobile
cleanroom. Those decreases were partially offset by an increase $85,000 related to the company’s Australian subsidiary’s activities
and a $39,000 increase in depreciation related to leasehold improvements and new equipment for the company’s manufacturing and lab
facilities.
The $129,000 increase in professional fees was
due to an increase of $72,000 in accounting fees associated with audit and compliance services, a $56,000 increase in recruiting expense,
a $54,000 increase in contract labor associated with pre-clinical and other research and development services, a $38,000 increase relating
to services for the company’s Australian subsidiary and an increase of $11,000 in director fees associated with adding a new member
to the company’s Board of Directors. These increases were partially offset by a decrease of $52,000 in general corporate legal fees
and $63,000 in scientific consulting associated with completed studies.
The $78,000 increase in payroll expense was due
to $135,000 in salary expense related to an increase in headcount, which was partially offset by a $56,000 decrease in stock-based compensation
related to employee stock option grants.
As a result of the changes in revenues and expenses
noted above, the company’s net loss decreased from $3.8 million in the three months ended September 30, 2022, to $3.0 million in
the three months ended September 30, 2023.
The condensed consolidated balance sheet for September
30, 2023, and the condensed consolidated statements of operations for the three and six month periods ended September 30, 2023 and 2022
follow at the end of this release.
Conference Call
Aethlon
Medical will hold a conference call today, Tuesday, November 14, 2023, at 4:30 p.m. ET to review its financial results for its second
quarter ended September 30, 2023 and recent corporate developments. Interested parties can register for the conference by navigating
to https://dpregister.com/sreg/10184181/fafb1d3fee. Please note that registered participants will receive their dial-in number
upon registration.
Interested parties without internet access or
who are unable to pre-register, may dial in as follows:
Participant Dial In (Toll Free): 1-844-836-8741
Participant International Dial In: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately
one hour after the end of the call through December 14, 2023. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529
(domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 2507359.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company
focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening
viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening
viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer,
where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S.
Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic
cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown
to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an
open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with
approved therapies.
Additional information can be found at www.AethlonMedical.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that
involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect,"
"intend," "plan," "project," "will," "projections," "estimate," "potentially"
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties
and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements
are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors
that may contribute to such differences include, without limitation, the Company's ability to successfully complete development of the
Hemopurifier and to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting;
the Company’s ability to initiate its oncology clinical trials in India and Australia; the Company’s ability to manage and
successfully complete its clinical trials, if initiated; the Company’s ability to raise additional capital and to maintain its Nasdaq
listing; the Company’s ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and
other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could
cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors"
in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities
and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release
speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake
any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
AETHLON MEDICAL, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
| |
September 30, 2023 | | |
March 31, 2023 | |
| |
| (unaudited) | | |
| | |
ASSETS | |
| | | |
| | |
CURRENT ASSETS | |
| | | |
| | |
Cash | |
$ | 10,175,920 | | |
$ | 14,532,943 | |
Prepaid expenses | |
| 311,397 | | |
| 557,623 | |
| |
| | | |
| | |
TOTAL CURRENT ASSETS | |
| 10,487,317 | | |
| 15,090,566 | |
| |
| | | |
| | |
Property and equipment, net | |
| 1,199,681 | | |
| 1,144,004 | |
Right-of-use lease asset | |
| 1,019,145 | | |
| 1,151,909 | |
Patents, net | |
| 1,375 | | |
| 1,650 | |
Restricted cash | |
| 87,506 | | |
| 87,506 | |
Deposits | |
| 33,305 | | |
| 33,305 | |
| |
| | | |
| | |
TOTAL ASSETS | |
$ | 12,828,329 | | |
$ | 17,508,940 | |
| |
| | | |
| | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |
| | | |
| | |
| |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Accounts payable | |
$ | 684,942 | | |
$ | 432,890 | |
Due to related parties | |
| 249,781 | | |
| 214,221 | |
Lease liability, current portion | |
| 279,737 | | |
| 269,386 | |
Other current liabilities | |
| 496,074 | | |
| 588,592 | |
| |
| | | |
| | |
TOTAL CURRENT LIABILITIES | |
| 1,710,534 | | |
| 1,505,089 | |
| |
| | | |
| | |
Lease liability, less current portion | |
| 798,451 | | |
| 939,642 | |
| |
| | | |
| | |
TOTAL LIABILITIES | |
| 2,508,985 | | |
| 2,444,731 | |
| |
| | | |
| | |
COMMITMENTS AND CONTINGENCIES | |
| | | |
| | |
| |
| | | |
| | |
EQUITY | |
| | | |
| | |
| |
| | | |
| | |
Common stock, par value of $0.001, 60,000,000 shares authorized; 2,492,908 and 2,299,259 issued and outstanding | |
| 2,493 | | |
| 2,299 | |
Additional-paid in capital | |
| 159,001,611 | | |
| 157,426,606 | |
Accumulated other comprehensive loss | |
| (9,570 | ) | |
| (6,141 | ) |
Accumulated deficit | |
| (148,675,190 | ) | |
| (142,358,555 | ) |
| |
| | | |
| | |
TOTAL STOCKHOLDERS' EQUITY | |
| 10,319,344 | | |
| 15,064,209 | |
| |
| | | |
| | |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | |
$ | 12,828,329 | | |
$ | 17,508,940 | |
AETHLON MEDICAL, INC. AND SUBSIDIARY
Consolidated Statements of Operations
For the three and six month periods ended September 30, 2023 and 2022
| |
Three Months | | |
Three Months | | |
Six Months | | |
Six Months | |
| |
Ended 9/30/23 | | |
Ended 9/30/22 | | |
Ended 9/30/23 | | |
Ended 9/30/22 | |
| |
| | |
| | |
| | |
| |
Government contract revenue | |
$ | – | | |
$ | – | | |
$ | – | | |
$ | – | |
| |
| | | |
| | | |
| | | |
| | |
OPERATING COSTS AND EXPENSES | |
| | | |
| | | |
| | | |
| | |
Professional fees | |
| 1,133,111 | | |
| 1,003,870 | | |
| 2,109,749 | | |
| 1,847,899 | |
Payroll and related | |
| 1,191,426 | | |
| 1,112,955 | | |
| 2,314,665 | | |
| 2,142,641 | |
General and administrative | |
| 850,809 | | |
| 1,548,484 | | |
| 2,159,092 | | |
| 2,582,505 | |
Total operating expenses | |
| 3,175,346 | | |
| 3,665,309 | | |
| 6,583,506 | | |
| 6,573,045 | |
| |
| | | |
| | | |
| | | |
| | |
OPERATING LOSS | |
| (3,175,346 | ) | |
| (3,665,309 | ) | |
| (6,583,506 | ) | |
| (6,573,045 | ) |
| |
| | | |
| | | |
| | | |
| | |
OTHER EXPENSE (INCOME) | |
| | | |
| | | |
| | | |
| | |
Loss on dissolution of subsidiary | |
| – | | |
| 142,121 | | |
| – | | |
| 142,121 | |
Interest and Other Income | |
| (140,890 | ) | |
| – | | |
| (266,871 | ) | |
| – | |
| |
| | | |
| | | |
| | | |
| | |
NET LOSS | |
$ | (3,034,456 | ) | |
$ | (3,807,430 | ) | |
$ | (6,316,635 | ) | |
$ | (6,715,166 | ) |
| |
| | | |
| | | |
| | | |
| | |
OTHER COMPREHENSIVE LOSS | |
| (2,435 | ) | |
| – | | |
| (3,429 | ) | |
| – | |
| |
| | | |
| | | |
| | | |
| | |
COMPREHENSIVE LOSS | |
$ | (3,036,891 | ) | |
$ | (3,807,430 | ) | |
$ | (6,320,064 | ) | |
$ | (6,715,166 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted net loss available to common stockholders per share | |
$ | (1.22 | ) | |
$ | (1.84 | ) | |
$ | (2.57 | ) | |
$ | (3.70 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted weighted average number of common shares outstanding | |
| 2,483,649 | | |
| 2,074,500 | | |
| 2,457,711 | | |
| 1,813,018 | |
v3.23.3
Cover
|
Nov. 14, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 14, 2023
|
Entity File Number |
001-37487
|
Entity Registrant Name |
AETHLON
MEDICAL, INC.
|
Entity Central Index Key |
0000882291
|
Entity Tax Identification Number |
13-3632859
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
11555
Sorrento Valley Road
|
Entity Address, Address Line Two |
Suite
203
|
Entity Address, City or Town |
San Diego
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
92121
|
City Area Code |
619
|
Local Phone Number |
941-0360
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.001 par value per share
|
Trading Symbol |
AEMD
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Aethlon Medical (NASDAQ:AEMD)
過去 株価チャート
から 3 2024 まで 4 2024
Aethlon Medical (NASDAQ:AEMD)
過去 株価チャート
から 4 2023 まで 4 2024